Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

188 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe.
Huang DB, Magnet S, De Angelis S, Holland TL, File TM Jr, Dryden M, Corey GR, Torres A, Wilcox MH. Huang DB, et al. Among authors: file tm jr. Diagn Microbiol Infect Dis. 2019 Feb;93(2):154-158. doi: 10.1016/j.diagmicrobio.2018.09.002. Epub 2018 Sep 10. Diagn Microbiol Infect Dis. 2019. PMID: 30266399 Free article.
Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections.
Huang DB, Corey GR, Holland TL, Lodise T, O'Riordan W, Wilcox MH, File TM Jr, Dryden M, Balser B, Desplats E, Torres A. Huang DB, et al. Among authors: file tm jr. Int J Antimicrob Agents. 2018 Aug;52(2):233-240. doi: 10.1016/j.ijantimicag.2018.05.012. Epub 2018 May 19. Int J Antimicrob Agents. 2018. PMID: 29783024 Free article. Clinical Trial.
A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study).
Holland TL, O'Riordan W, McManus A, Shin E, Borghei A, File TM Jr, Wilcox MH, Torres A, Dryden M, Lodise T, Oguri T, Corey GR, McLeroth P, Shukla R, Huang DB. Holland TL, et al. Among authors: file tm jr. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02580-17. doi: 10.1128/AAC.02580-17. Print 2018 May. Antimicrob Agents Chemother. 2018. PMID: 29530858 Free PMC article. Clinical Trial.
Surveillance of iclaprim activity: In vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and Europe.
Huang DB, File TM Jr, Dryden M, Corey GR, Torres A, Wilcox MH. Huang DB, et al. Among authors: file tm jr. Diagn Microbiol Infect Dis. 2018 Apr;90(4):329-334. doi: 10.1016/j.diagmicrobio.2017.12.001. Epub 2017 Dec 7. Diagn Microbiol Infect Dis. 2018. PMID: 29306582 Free article.
The effect of pulmonary surfactant on the in vitro activity of Iclaprim against common respiratory bacterial pathogens.
Huang DB, Duncan LR, Flamm RK, Dryden M, Corey GR, Wilcox MH, Torres A, File TM Jr. Huang DB, et al. Among authors: file tm jr. Diagn Microbiol Infect Dis. 2018 Jan;90(1):64-66. doi: 10.1016/j.diagmicrobio.2017.09.011. Epub 2017 Sep 20. Diagn Microbiol Infect Dis. 2018. PMID: 29103875 Free article.
A Phase II Randomized, Double-blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-positive Pathogens.
Huang DB, File TM Jr, Torres A, Shorr AF, Wilcox MH, Hadvary P, Dryden M, Corey GR. Huang DB, et al. Among authors: file tm jr. Clin Ther. 2017 Aug;39(8):1706-1718. doi: 10.1016/j.clinthera.2017.07.007. Epub 2017 Jul 27. Clin Ther. 2017. PMID: 28756068 Free article. Clinical Trial.
Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
File TM Jr, Eckburg PB, Talbot GH, Llorens L, Friedland HD. File TM Jr, et al. Int J Antimicrob Agents. 2017 Aug;50(2):247-251. doi: 10.1016/j.ijantimicag.2017.01.043. Epub 2017 Jun 6. Int J Antimicrob Agents. 2017. PMID: 28599867 Clinical Trial.
Reply to Bush and Kaye.
Kullar R, Goff DA, Bauer KA, File TM Jr. Kullar R, et al. Among authors: file tm jr. Clin Infect Dis. 2017 Oct 16;65(9):1596. doi: 10.1093/cid/cix531. Clin Infect Dis. 2017. PMID: 28591832 No abstract available.
188 results
Jump to page